Busulfan–fludarabine‐ or treosulfan–fludarabine‐based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties

This article summarizes a study published in the British Journal of Haematology that examines the outcomes of hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD) using different conditioning regimens. The study found that both busulfan-fludarabine (bu-flu) and treosulfan-fludarabine (treo-flu) regimens resulted in excellent overall survival rates and low rates of acute and chronic graft-versus-host disease (GVHD) and graft failure. However, treo-flu had a higher incidence of chronic GVHD and extensive chronic GVHD, but a lower frequency of gonadal damage compared to bu-flu. The study emphasizes the potential of HSCT with myeloablative conditioning in treating SCD patients. The report provides a culturally sensitive and comprehensive analysis of the topic, making it a valuable resource for library patrons conducting research on this subject. [Extracted from the article]